Strand Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 103

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $96.7M

  • Investors
  • 18

Strand Therapeutics General Information

Description

Provider of biotechnology services intended to create gene therapies powered by synthetic biology. The company's offerings include immunotherapies to produce target cancer-killing proteins during immunotherapy, enabling patients to improve their body's immune system to fight cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 20 Overland Street
  • Suite A
  • Boston, MA 02215
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
LOHAS & Wellness, Life Sciences, Oncology
Corporate Office
  • 20 Overland Street
  • Suite A
  • Boston, MA 02215
  • United States
+1 (617)

Strand Therapeutics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Strand Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series A) 28-Nov-2022 $96.7M Completed Pre-Clinical Trials
8. Grant 17-May-2021 Completed Pre-Clinical Trials
7. Grant 15-May-2021 Completed Pre-Clinical Trials
6. Debt - PPP 12-Apr-2020 Completed Pre-Clinical Trials
5. Seed Round 04-Jun-2019 Completed Pre-Clinical Trials
4. Accelerator/Incubator 15-May-2019 Completed Pre-Clinical Trials
3. Accelerator/Incubator 19-Oct-2018 Completed Startup
2. Grant 13-Mar-2018 $2K Completed Startup
1. Accelerator/Incubator 01-Jan-2018 Completed Startup
To view Strand Therapeutics’s complete valuation and funding history, request access »

Strand Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-2
Series A-1
Series A 7,257,044 $0.000010 $5.81 $5.81 1x $5.81 22.57%
Seed 5,886,624 $0.000010 $1 $1 1x $1 18.31%
To view Strand Therapeutics’s complete cap table history, request access »

Strand Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Provider of biotechnology services intended to create gene therapies powered by synthetic biology. The company's offerin
Drug Discovery
Boston, MA
103 As of 2024

Philadelphia, PA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Strand Therapeutics Competitors (63)

One of Strand Therapeutics’s 63 competitors is Carisma Therapeutics, a Formerly VC-backed company based in Philadelphia, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Carisma Therapeutics Formerly VC-backed Philadelphia, PA
WaVe Life Sciences Formerly VC-backed Cambridge, MA
NexImmune Formerly VC-backed Gaithersburg, MD
Gadeta Formerly VC-backed Utrecht, Netherlands
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
You’re viewing 5 of 63 competitors. Get the full list »

Strand Therapeutics Patents

Strand Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023262576-A1 Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof Pending 26-Apr-2022
CA-3225907-A1 Polynucleotides and uses thereof Pending 03-Aug-2021
AU-2022323516-A1 Polynucleotides and uses thereof Pending 03-Aug-2021
EP-4381080-A1 Polynucleotides and uses thereof Pending 03-Aug-2021
US-20240360472-A1 Polynucleotides and uses thereof Pending 03-Aug-2021 C12N15/86
To view Strand Therapeutics’s complete patent history, request access »

Strand Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Strand Therapeutics Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds
ATMA Capital Venture Capital Minority
BeiGene Corporation Minority
Camford Capital Venture Capital Minority
DHVC Venture Capital Minority
Eli Lilly and Company Corporation Minority
You’re viewing 5 of 18 investors. Get the full list »

Strand Therapeutics FAQs

  • When was Strand Therapeutics founded?

    Strand Therapeutics was founded in 2017.

  • Where is Strand Therapeutics headquartered?

    Strand Therapeutics is headquartered in Boston, MA.

  • What is the size of Strand Therapeutics?

    Strand Therapeutics has 103 total employees.

  • What industry is Strand Therapeutics in?

    Strand Therapeutics’s primary industry is Drug Discovery.

  • Is Strand Therapeutics a private or public company?

    Strand Therapeutics is a Private company.

  • What is the current valuation of Strand Therapeutics?

    The current valuation of Strand Therapeutics is .

  • What is Strand Therapeutics’s current revenue?

    The current revenue for Strand Therapeutics is .

  • How much funding has Strand Therapeutics raised over time?

    Strand Therapeutics has raised $103M.

  • Who are Strand Therapeutics’s investors?

    ATMA Capital, BeiGene, Camford Capital, DHVC, and Eli Lilly and Company are 5 of 18 investors who have invested in Strand Therapeutics.

  • Who are Strand Therapeutics’s competitors?

    Carisma Therapeutics, WaVe Life Sciences, NexImmune, Gadeta, and CRISPR Therapeutics are some of the 63 competitors of Strand Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »